Timber Pharmaceuticals, Inc. (AMEX:TMBR) Appoints Alan Mendelsohn, M.D., as Chief Medical Officer

On 01-28-2k21 (Thursday) Shareholders tracking shares of Timber Pharmaceuticals, Inc. (TMBR) belongs to Healthcare sector and Biotechnology industry. TMBR flaunted -12.93% to reach at $1.28 during previous trading session. TMBR Inc. has a total market value of 15.04M at the time of writing – representing $18.89M outstanding shares. Turning to other widely-considered trading data, this company’s half yearly performance is observed at -32.98%.

Timber Pharmaceuticals, Inc. ( TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced the appointment of Alan Mendelsohn, M.D., as Chief Medical Officer. Dr. Mendelsohn assumes the roles and responsibilities of Amir Tavakkol, Ph.D., who will be stepping down as the Company’s Chief Scientific Officer.

“We are pleased to welcome Dr. Mendelsohn to our management team. Dr. Mendelsohn recently supported the approval and launch of a new treatment for moderate to severe plaque psoriasis and has a deep understanding of clinical development and medical commercialization in dermatology,” said John Koconis, Chief Executive Officer of Timber. “We also thank Dr. Tavakkol for his support in establishing a strong scientific platform for us to build on as we advance into clinical stage research.”

Dr. Mendelsohn is a board-certified pediatric cardiologist with more than 20 years of experience in clinical development and medical affairs. Prior to joining Timber, he served as Associate Vice president of Dermatology Medical Affairs for Sun Pharmaceuticals Industries. Previously Dr. Mendelsohn led the U.S. rheumatology medical affairs team for Pfizer as a Senior Director and was Senior Director of Immunology Research and Development for Janssenwhere he worked on both rheumatology and dermatology indications. He has also served in various leadership roles at Centocor, Inc., a Johnson & Johnson company. Dr. Mendelsohn holds a medical degree from the State University of New York Health Science Center at Brooklyn.

“This is an exciting time to join Timber as the Company continues to enroll patients in important studies for underserved dermatologic diseases including congenital ichthyosis and facial angiofibromas in tuberous sclerosis complex,” said Dr. Mendelsohn. “I hope to use my experience to help our Timber team successfully navigate the clinical development process through regulatory reviews and look forward to serving patients and families living with these rare conditions. As a former practicing pediatric cardiologist, I have and will continue to focus my passion on developing treatments for the underserved.”

Volume Evaluation

The USA listed company saw a recent price trade of $1.28 and 22,270,984 shares have traded hands in the session. There are 4.24M shares which are traded as an average over the last three months period.

Many investors forget that one of the defining characteristics of the stock market is that it’s a market. Buyers and sellers help determine the price of each stock, and the more buyers and sellers a particular stock has interested in it, the more liquid the market will be. Liquidity can have a profound impact on just how violently stock prices can move in either direction, and the reasons have to do with the nature of the market in a stock’s shares.

Trading volume, or volume, is the number of shares or contracts that indicates the overall activity of a security or market for a given period. Trading volume is an important technical indicator an investor uses to confirm a trend or trend reversal. Volume gives an investor an idea of the price action of a security and whether they should buy or sell the security.

Performance Levels

Looking performance record on shares of Timber Pharmaceuticals, Inc. (TMBR) we observed that the stock has seen a move -86.29% over the last 52-week trading period. The stock generated performance of 30.87% tracking last 3 months. Investors will be anxiously watching to see if things will turn around and the stock will start gaining or losing momentum over the next few months. If we look back year-to-date, the stock has performed 72.27%. Shares are at 14.29% over the previous week and 66.23% over the past month.

Analyst Views:

Fluctuating the focus to what the Wall Street analysts are projecting, we can see that the current consensus target price on shares is $0. Analysts often put in a lot of work to study stocks that they cover. Wall Street analysts have a consensus recommendation of 3.00on this stock. This number falls on a one to five scale where a 1 would be considered a strong buy and 5 means a strong sell, 2 shows Buy, 3 Hold, 4 reveals Sell recommendation.

Volatility Insights

Watching some historical volatility numbers on shares of Timber Pharmaceuticals, Inc. (TMBR) we can see that the 30 days volatility is presently 15.95%. The 7 days volatility is 23.41%. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.

The company has a beta of 0.38. 1.00 indicates that its price is correlated with the market. Less than 1.00 shows less volatility than the market. Beta greater than 1.00 indicates that the security’s price is theoretically more volatile than the market.

The Average True Range (ATR) value reported at 0.17. The average true range (ATR) is a technical analysis indicator that measures volatility by decomposing the entire range of an asset price for that period. A stock experiencing a high level of volatility has a higher ATR, and a low volatility stock has a lower ATR. The ATR may be used by market technicians to enter and exit trades, and it is a useful tool to add to a trading system. It was created to allow traders to more accurately measure the daily volatility of an asset by using simple calculations. The indicator does not indicate the price direction; rather it is used primarily to measure volatility caused by gaps and limit up or down moves. The ATR is fairly simple to calculate and only needs historical price data.

Technical Considerations

Timber Pharmaceuticals, Inc. (TMBR) stock positioned -32.70% distance from the 200-day MA and stock price situated 29.39% away from the 50-day MA while located 31.28% off of the 20-day MA.

RSI value sited with reading of 54.55. Relative Strength Index (RSI) is an extremely useful and popular momentum oscillator. The RSI compares the magnitude of a stock’s recent gains to the magnitude of its recent losses and turns that information into a number that ranges from 0 to 100. It takes a single parameter, the number of time periods to use in the calculation. In his book, Wilder recommends using 14 periods.

Observing the Technical Indicators:

Timber Pharmaceuticals, Inc. institutional ownership is held at 12.30% while insider ownership was 45.20%. As of now, TMBR has a P/S, P/E and P/B values of 37.60, 0 and 0 respectively. Its P/Cash is valued at 1.25. The Company’s net profit margin for the 12 months at 0. Comparatively, the gazes have a Gross margin 0.

Profitability ratios:

Looking into the profitability ratios of TMBR stock, an investor will find its ROE, ROA, ROI standing at 956.00%, -219.50% and 0, respectively.

Earnings per Share Details of Timber Pharmaceuticals, Inc.:

The EPS of TMBR is strolling at -2.60, measuring its EPS growth this year at 66.40%. As a result, the company has an EPS growth of 0 for the approaching year.

Given the importance of identifying companies that will ensure earnings per share at a tall rate, we later obsession to umpire how to identify which companies will achieve high amassing rates. One obvious showing off to identify high earnings per portion count together companies are to locate companies that have demonstrated such build up beyond the p.s. 5 to 10 years.

The payout ratio shows the proportion of earnings paid out as dividends to shareholders, typically expressed as a percentage of the company’s earnings. The payout ratio can also be expressed as dividends paid out as a proportion of cash flow. The payout ratio is also known as the dividend payout ratio. The Company’s payout ratio was 0 and Price to free cash flow remained $0.

About Reynolds Smith

Myself Reynolds Smith and I am energetic about business and Healthcare & Biotech news with more than 11 years in the industry, beginning my venture as an author and later on climbing my way up into senior positions. I am the main stimulus behind Alphafinews.com started off with a dream to expand the organization’s reach out on a global scale. My writing style is diversifying, I write on a variety of topics but my personal favorite is lifestyle and business. I love communicating myself through artistic and innovative means such as writing, and painting. When I’m not doing any specific field related work, I enjoy spending some time with my dog, playing hockey or meeting my friends and family members. I never give up. I like French fries and Belgian waffles. I am an editor and contributor of the Health segment. I undergo critical analysis of corporations and extract the most significant information for our rich investor network.

View all posts by Reynolds Smith →